Introduction

  • Constitutes 5-15% of all juvenile idiopathic arthritis cases.
  • Lacks specific sex predilection, affecting boys and girls equally.
  • Peak age of onset typically 1-5 years.

Pathophysiology

Immune System Dysregulation

  • Classified fundamentally as an autoinflammatory disorder.
  • Primarily affects innate immune system rather than adaptive immunity.
  • Lacks classic autoreactive T cells and autoantibodies.

Cytokine Profile

  • Interleukin-1 (IL-1) family cytokines serve as key pathogenic drivers.
  • Marked elevation in interleukin-6 (IL-6) drives systemic inflammatory manifestations.
  • Interleukin-18 (IL-18) acts as central driver, showing significant serum elevation.

Clinical Manifestations

Systemic Features

  • Fever: Intermittent, high-spiking quotidian fever exceeding 39°C. Peaks once or twice daily, typically evening. Rapid return to normal or subnormal baseline.
  • Rash: Evanescent, salmon-pink, maculopapular eruptions. Distributed mainly over trunk and proximal extremities. Migratory, nonpruritic, transient lasting less than one hour. Demonstrates Koebner phenomenon, evoked by superficial trauma or heat.
  • Visceral Involvement: Generalized lymphadenopathy, hepatosplenomegaly.
  • Serositis: Pleuritis and pericarditis common; myocarditis rare.

Articular Features

  • Arthritis often absent at initial presentation, developing later in disease course.
  • Symmetrical polyarticular pattern common, affecting knees, wrists, ankles, cervical spine, hips.

Diagnostic Framework

Table 1: Classification Criteria For Systemic Juvenile Idiopathic Arthritis

Criterion TypeSpecific Requirements
MandatoryArthritis in $\ge$ 1 joint with or preceded by documented quotidian fever $\ge$ 2 weeks (daily for $\ge$ 3 days)
Additive (Requires $\ge$ 1)Evanescent erythematous rash
Generalized lymph node enlargement
Hepatomegaly or splenomegaly
Serositis
ExclusionsPsoriasis in patient or first-degree relative
HLA-B27 positive male onset > 6 years
Ankylosing spondylitis, enthesitis-related arthritis, inflammatory bowel disease in relative
Positive IgM rheumatoid factor twice, 3 months apart

Laboratory Investigations

Inflammatory Markers

  • Extreme leukocytosis featuring neutrophilia.
  • Marked thrombocytosis.
  • Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
  • Severe hyperferritinemia.
  • Elevated serum S100A8, S100A9, and S100A12 levels.

Hematologic And Immunologic Profile

  • Microcytic anemia secondary to severe inflammation-induced iron sequestration.
  • Rheumatoid factor (RF) and antinuclear antibodies (ANA) classically negative.

Severe Complications

Macrophage Activation Syndrome

  • Life-threatening complication occurring in 5-8% of cases overtly, subclinical in up to 30%.
  • Driven by excessive activation of macrophages and T lymphocytes.
  • Clinical shift: Fever becomes unremitting.
  • New onset central nervous system encephalopathy.
  • Dramatic laboratory shift: Sudden drop in erythrocyte sedimentation rate (ESR) due to hypofibrinogenemia.
  • Rapid development of pancytopenia (leukopenia, thrombocytopenia) replacing previous elevations.
  • Extreme hyperferritinemia (>10,000 ng/mL), hypertriglyceridemia, elevated hepatic transaminases.

Inflammatory Lung Disease

  • Rare, potentially fatal complication.
  • Predominant pathology features pulmonary alveolar proteinosis and endogenous lipoid pneumonia.
  • Associated with younger age onset, prior macrophage activation syndrome, and high IL-18.

Algorithmic Management

Table 2: Stepwise Pharmacotherapy For Systemic Juvenile Idiopathic Arthritis

Treatment TierPharmacologic AgentsIndications & Efficacy
First LineNonsteroidal anti-inflammatory drugs (NSAIDs)Initial symptomatic relief; rarely controls severe systemic disease alone.
Bridge / SevereSystemic CorticosteroidsControls severe systemic illness, macrophage activation syndrome. Avoid long-term use.
Targeted BiologicsIL-1 Inhibitors (Anakinra, Canakinumab)Highly effective for profound systemic features; often initiates rapid remission.
Targeted BiologicsIL-6 Inhibitors (Tocilizumab)Controls refractory systemic disease, normalizes acute phase reactants.
ConventionalMethotrexateAdjunctive therapy primarily targeting persistent articular involvement.
  • Tumor necrosis factor (TNF) inhibitors remain less effective for systemic symptoms compared to IL-1 and IL-6 blockade.
  • Emergent intravenous methylprednisolone pulse therapy alongside cyclosporine required for macrophage activation syndrome.